Life Science Investing ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer
Life Science Investing ALX Oncology Doses First Patient in Phase 1 Dose Escalation Trial Evaluating ADC ALX2004 for the Treatment of EGFR-Expressing Solid Tumors
Revolve Receives Approval from the Alberta Utilities Commission for the 15.7 MW Bright Meadows Solar Project
